These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26328636)

  • 1. The Effects of Allopurinol on the Carotid Intima-media Thickness in Patients with Type 2 Diabetes and Asymptomatic Hyperuricemia: A Three-year Randomized Parallel-controlled Study.
    Liu P; Wang H; Zhang F; Chen Y; Wang D; Wang Y
    Intern Med; 2015; 54(17):2129-37. PubMed ID: 26328636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
    Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
    PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of uric acid-lowering therapy in patients with essential arterial hypertension.
    Gruszka K; Drożdż T; Wojciechowska W; Jankowski P; Terlecki M; Bijak M; Hering D; Bilo G; Drożdż D; Rajzer M
    Blood Press Monit; 2022 Jun; 27(3):152-160. PubMed ID: 35120026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study.
    Liu P; Chen Y; Wang B; Zhang F; Wang D; Wang Y
    Clin Endocrinol (Oxf); 2015 Oct; 83(4):475-82. PubMed ID: 25400252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of C-reactive protein with early-stage carotid atherosclerosis in Japanese patients with early-state type 2 diabetes mellitus.
    Mita T; Watada H; Uchino H; Shimizu T; Hirose T; Tanaka Y; Kawamori R
    Endocr J; 2006 Oct; 53(5):693-8. PubMed ID: 16926521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
    Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K;
    Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia.
    Takir M; Kostek O; Ozkok A; Elcioglu OC; Bakan A; Erek A; Mutlu HH; Telci O; Semerci A; Odabas AR; Afsar B; Smits G; ALanaspa M; Sharma S; Johnson RJ; Kanbay M
    J Investig Med; 2015 Dec; 63(8):924-9. PubMed ID: 26571421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
    Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.
    Kanbay M; Huddam B; Azak A; Solak Y; Kadioglu GK; Kirbas I; Duranay M; Covic A; Johnson RJ
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):1887-94. PubMed ID: 21784838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood glucose fluctuations detected by continuous glucose monitoring system in gout patients with normal glucose tolerance and the effect of urate-lowering therapy.
    Mu Z; Wang J; Wang W; Lv W; Chen Y; Wang F; Zhao Y; Dong B; Wang Y; Wang Z
    Int J Rheum Dis; 2020 Aug; 23(9):1145-1151. PubMed ID: 32483927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease.
    Gonzalez-Gay MA; Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Gomez-Acebo I; Miranda-Filloy JA; Paz-Carreira J; Martin J; Llorca J
    Semin Arthritis Rheum; 2009 Dec; 39(3):157-62. PubMed ID: 18722649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uric acid is an important predictor for hypertensive early atherosclerosis.
    Mutluay R; Deger SM; Bahadir E; Durmaz AO; Citil R; Sindel S
    Adv Ther; 2012 Mar; 29(3):276-86. PubMed ID: 22392103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the Xanthine Oxidase Inhibitor, Febuxostat, on WBC Count in Asymptomatic Hyperuricemia: Subanalysis of the Randomized PRIZE Study.
    Takeshita M; Tanaka A; Yoshida H; Nakamura I; Shibata Y; Hata S; Kushiyama A; Okutsu M; Ishizu T; Node K
    J Atheroscler Thromb; 2024 Jun; 31(6):864-875. PubMed ID: 38220209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein as a marker of progression of carotid atherosclerosis in subjects with type 2 diabetes mellitus.
    Pleskovič A; Letonja MŠ; Vujkovac AC; Nikolajević Starčević J; Gazdikova K; Caprnda M; Gaspar L; Kruzliak P; Petrovič D
    Vasa; 2017 May; 46(3):187-192. PubMed ID: 28218562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):182-183. PubMed ID: 29125593
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
    J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of concordance between plasma markers of cardiovascular risk and intima-media thickness in patients with type 2 diabetes.
    Moussavi N; Renier G; Roussin A; Mamputu JC; Buithieu J; Serri O
    Diabetes Obes Metab; 2004 Jan; 6(1):69-77. PubMed ID: 14686966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.